




NEOVIRTECH

Discovery made easy!



At NeoVirTech we have developed an ever-expanding catalogue of autofluorescent viruses and viral vectors for the direct imaging of antiviral drug candidates or disinfection procedure in the field of human/animal health and biodefense.

OUR ANCHOR™ SOLUTION.



How are we different?


No fixation, no extraction, no reagents, cost efficient.

Save time !

We autonomously visualize viral DNA replication in living cells.

No false positives: only marks infectious particles (contrary to qPCR). Our technology allows quantitative and qualitative results of infection and viral replication.


- ▶ hCMV replication center
- ▶ hCMV DNA in the nucleus (single particle)
- ▶ hCMV DNA in the cytoplasm (single particle)



Real-time monitoring and quantification of viral replication and infection


Workflow antiviral screening and validation

We can support you in the development of your antiviral molecules.
From compound screening to *in vivo* validation



Workflow for accelerated measurement of disinfection processes

Step 1 : choose a fast and relevant viral model.




Here we selected Adenovirus Type 5


- Rapid viral cycle
- Simple permissive cultured cells
- Tagged ANCHOR
- Result in 24h
- HCS compatible
- "disinfection resistant"

Step 2: Measure the efficiency of the disinfection process of your solution in different conditions (time, virus, type of support...) to calibrate your final product.


Adv5 ANCHOR on glass



Adv5 ANCHOR on surgical masks



Step 3: Validation of the characteristics of your final product in order to reduce the cost of your normative tests. We provide before/after images for communication and marketing applications.



SARS-CoV-2 testing

Our services:

Virology



- ANCHOR™ imaging
- Classical virology methods (CPE/qPCR)
- Antiviral assay from *in vitro* to *in vivo*
- Infectious viruses in BSL2 / BSL3
- Vaccinal strains
- Oncolytic viruses

Drug discovery



- Toxicity assay
- High content screening
- Dose response (IC50/90 calculation)
- Mechanism of action
- Resistant strains generation and target identification
- Combinatorial studies

Imaging



- Viral and non-viral context
- High content imaging and quantification
- High resolution imaging

Disinfection testing



- From early stage to validation of commercial product
- All surfaces
- Living Human Skin explants

Oncolytic virotherapies



- Screening / validation
- Interaction between oncolytic viruses and preexisting treatments
- *In vivo* testing

You need more information ? Contact us!



NeoVirTech, SAS
1 place Pierre Potier, Oncopole, entrée B
31106 Toulouse
France



contact@neovirtech.com
+33972405413
www.neovirtech.com





Virology



Drug discovery



Imaging



Disinfection testing



Oncolytic virotherapies

The viruses we have at our disposal to advance your projects

HUMAN MARKET	
Herpesvirus	hCMV ANCHOR™ (WT / Letermovir resistant / Ganciclovir resistant) EBV ANCHOR™ (in validation) HSV1 ANCHOR™ (in validation)
Poxvirus	<u>Vaccinia virus ANCHOR*</u>
Retrovirus	Lentivirus HIV1 derived ANCHOR™ (several including IN deficient) HIV1 ANCH (in coll.)
Adenovirus	hAdv5 ANCHOR™
Other viruses	Respiratory Syncytial Virus Influenza Rhinovirus SARS-CoV-2 (pré-VOC, delta, omicron)

ANIMAL MARKET	
Poxvirus	Myxomavirus (Vaccinal and pathogenous strain ANCHOR™)* <u>Cowpox ANCHOR™</u> <u>African Swine Fever Virus ANCHOR™ (in coll.)</u>
Herpesvirus	Equine HV1 ANCHOR™
Other viruses	Feline Calicivirus Canine parvovirus

Viruses having biodefense applications are underlined.

* *in vivo* efficacy testing available

Your virus of interest is not in this list ?

Do not hesitate to contact us, we will find a solution !